QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - January 10, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan FoxNEW YORK, NY - January 9, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026NEW YORK, NY - January 8, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026NEW YORK, NY - January 7, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026NEW YORK, NY - January 6, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action LawsuitNEW YORK, NY - January 5, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action LawsuitNEW YORK, NY - January 3, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action LawsuitNEW YORK, NY - January 2, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action LawsuitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action LawsuitNEW YORK, NY - January 1, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) ShareholdersNEW YORK, NY - December 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(
NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) ShareholdersSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesTORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (
NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesTORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (
NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (
NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
